Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1981 8
1983 1
1985 4
1986 1
1988 3
1989 1
1990 3
1991 2
1992 1
1993 1
1994 1
1997 1
1999 1
2000 2
2001 2
2002 4
2003 4
2004 5
2005 6
2006 2
2007 3
2008 1
2009 3
2010 2
2011 1
2012 5
2013 5
2014 3
2015 2
2017 1
2020 3
2021 1
2022 1
2023 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.
Zalacain-Vicuña AJ, Nieto C, Picas J, Martínez H, Bermejo R, Corrales A, Campos FF, Igea SA, Otero-Espinar FJ, Briones VG. Zalacain-Vicuña AJ, et al. Mycoses. 2023 Jul;66(7):566-575. doi: 10.1111/myc.13543. Epub 2022 Nov 17. Mycoses. 2023. PMID: 36336989 Clinical Trial.
BACKGROUND: A new water-soluble formulation with ciclopirox has shown a higher penetration than other ciclopirox nail lacquers currently marketed, thus providing a higher concentration of ciclopirox into the nail. OBJECTIVE: To evaluate the efficacy and safet …
BACKGROUND: A new water-soluble formulation with ciclopirox has shown a higher penetration than other ciclopirox nail lacquers …
A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis.
Squire RA, Goode K. Squire RA, et al. J Dermatolog Treat. 2002 Jun;13(2):51-60. doi: 10.1080/095466302317584395. J Dermatolog Treat. 2002. PMID: 12060502 Free article. Clinical Trial.
Symptoms include scalp itchiness and scaling. Due to its antimycotic activity, ciclopirox olamine is established as an effective treatment for these scalp conditions. Salicylic acid has keratolytic properties and aids in the removal of scales. OBJECTIVE: To compare the the …
Symptoms include scalp itchiness and scaling. Due to its antimycotic activity, ciclopirox olamine is established as an effective trea …
Diode Laser and Red-Laser Photodynamic Therapy Versus Ciclopirox 8% HPCH Nail Lacquer for the Treatment of Onychomycosis: A Randomised Controlled Trial.
García-Oreja S, Álvaro-Afonso FJ, Navarro-Pérez D, León-Herce D, Tardáguila-García A, Lázaro-Martínez JL. García-Oreja S, et al. Mycoses. 2025 Oct;68(10):e70121. doi: 10.1111/myc.70121. Mycoses. 2025. PMID: 41024682 Free PMC article. Clinical Trial.
Participants received either eight sessions of laser treatment combined with three sessions of photodynamic therapy, or daily treatment with ciclopirox 8% HPCH. RESULTS: The clinical cure rate was 94.1% in the group treated with laser and photodynamic therapy, compared to …
Participants received either eight sessions of laser treatment combined with three sessions of photodynamic therapy, or daily treatment with …
Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox.
Romero-Cerecero O, Zamilpa A, Jiménez-Ferrer JE, Rojas-Bribiesca G, Román-Ramos R, Tortoriello J. Romero-Cerecero O, et al. Planta Med. 2008 Oct;74(12):1430-5. doi: 10.1055/s-2008-1081338. Epub 2008 Jul 31. Planta Med. 2008. PMID: 18671197 Clinical Trial.
A similar lacquer solution containing 8 % ciclopirox was used as control. Treatments were assigned randomly and administered topically for 6 months. ...
A similar lacquer solution containing 8 % ciclopirox was used as control. Treatments were assigned randomly and administered topicall …
Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis.
Aly R, Maibach HI, Bagatell FK, Dittmar W, Hänel H, Falanga V, Leyden JJ, Roth HL, Stoughton RB, Willis I, et al. Aly R, et al. Clin Ther. 1989 May-Jun;11(3):290-303. Clin Ther. 1989. PMID: 2663159 Clinical Trial.
Minor localized side effects (pruritus, burning sensation) were reported in 2% of 89 patients treated with ciclopirox olamine lotion 1%. The results demonstrate the bioequivalence of ciclopirox olamine lotion 1% and ciclopirox olamine cream 1% and confirm the …
Minor localized side effects (pruritus, burning sensation) were reported in 2% of 89 patients treated with ciclopirox olamine lotion …
Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
Schalka S, Nunes S, Gomes Neto A. Schalka S, et al. An Bras Dermatol. 2012 Jan-Feb;87(1):19-25. doi: 10.1590/s0365-05962012000100002. An Bras Dermatol. 2012. PMID: 22481647 Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of a nail lacquer formulation containing ciclopirox 8% in two different posologies: the traditional regimen (3/2/1) and a regimen of weekly use. ...CONCLUSION: The nail lacquer containing ciclopirox 8% was equally effec …
OBJECTIVE: To evaluate the efficacy and safety of a nail lacquer formulation containing ciclopirox 8% in two different posologies: th …
Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis.
Ratnavel RC, Squire RA, Boorman GC. Ratnavel RC, et al. J Dermatolog Treat. 2007;18(2):88-96. doi: 10.1080/16537150601092944. J Dermatolog Treat. 2007. PMID: 17520465 Free article. Clinical Trial.
BACKGROUND: Ciclopirox olamine (CPO) is a broad-spectrum antifungal with anti-inflammatory properties effective against the yeast implicated in seborrhoeic dermatitis, Malassezia spp. ...
BACKGROUND: Ciclopirox olamine (CPO) is a broad-spectrum antifungal with anti-inflammatory properties effective against the yeast imp …
Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris.
Bogaert H, Cordero C, Ollague W, Savin RC, Shalita AR, Zaias N. Bogaert H, et al. J Int Med Res. 1986;14(4):210-6. doi: 10.1177/030006058601400408. J Int Med Res. 1986. PMID: 3530834 Clinical Trial.
In separate multicentre, randomized, double-blind clinical trials, 1% ciclopirox olamine cream was compared with its cream vehicle and with 1% clotrimazole cream as treatment for tinea corporis and tinea cruris. ...These results were maintained through the two-week drug-fr …
In separate multicentre, randomized, double-blind clinical trials, 1% ciclopirox olamine cream was compared with its cream vehicle an …
Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial.
Lebwohl M, Plott T. Lebwohl M, et al. Int J Dermatol. 2004 Jul;43 Suppl 1:17-20. doi: 10.1111/j.1461-1244.2004.02409.x. Int J Dermatol. 2004. PMID: 15271196 Clinical Trial.
RESULTS: Ciclopirox was significantly better than vehicle in effectively treating seborrheic dermatitis. 'Effective treatment' (score of 0 or 1 for disease status, scaling and erythema) was achieved in 26.0% of ciclopirox-treated patients compared with 12.9% of vehi …
RESULTS: Ciclopirox was significantly better than vehicle in effectively treating seborrheic dermatitis. 'Effective treatment' (score …
Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.
Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML. Sen S, et al. Exp Hematol. 2013 Sep;41(9):799-807.e4. doi: 10.1016/j.exphem.2013.04.012. Epub 2013 May 6. Exp Hematol. 2013. PMID: 23660068 Free PMC article. Clinical Trial.
We also demonstrate that the ability of ciclopirox to inhibit mTOR is specific to ciclopirox because neither iron chelators nor other eIF5A inhibitors affect mTOR activity, even at high doses. We have thus identified a novel function of ciclopirox that might …
We also demonstrate that the ability of ciclopirox to inhibit mTOR is specific to ciclopirox because neither iron chelators no …
81 results